{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:48:03Z","timestamp":1786376883680,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mesalazine is a key drug used for remission induction and maintenance therapy in inflammatory bowel disease (IBD). We sometimes encounter patients who develop allergic reactions to the drug and inevitably discontinue treatment. Of 692 patients who received mesalazine for IBD between 2014 and March 2020, 33 diagnosed with mesalazine allergy (43 episodes) were included, and their clinical manifestations were evaluated. For ten patients undergoing desensitization therapy, therapeutic outcomes were evaluated. The incidence of mesalazine allergy was 4.8%. The time from the start of oral medication to allergy onset was 10\u2009\u00b1\u20095\u00a0days for the first allergic attack and 2\u2009\u00b1\u20091\u00a0days for the second and subsequent allergic attacks. The observed clinical symptoms included fever (93%), diarrhea (26%), abdominal pain (23%), and bloody stool (12%). Drug-induced lymphocyte stimulation test was performed in 85% of the patients (28\/33), and the sensitivity was 51%. Desensitization therapy with a time-dependent mesalazine granule formulation was successful in nine of the ten patients (90%), allowing them to receive 2000\u00a0mg or more of the drug. Fever was a common allergic symptom, and its presence appeared to be useful for distinguishing mesalazine allergy from exacerbation of the primary disease. Desensitization therapy was useful in patients with mesalazine allergy.<\/jats:p>","DOI":"10.1038\/s41598-020-79207-z","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T11:07:12Z","timestamp":1608203232000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7802-3980","authenticated-orcid":false,"given":"Satohiro","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirosato","family":"Mashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,17]]},"reference":[{"key":"79207_CR1","first-page":"1188","volume":"88","author":"S Hanauer","year":"1993","unstructured":"Hanauer, S. et al. Mesalamine capsules for treatment of active ulcerative colitis: Results of a controlled trial. Pentasa Study Group. Am. J. Gastroenterol. 88, 1188\u20131197 (1993).","journal-title":"Am. J. Gastroenterol."},{"key":"79207_CR2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4292\/wjgpt.v1.i6.132","volume":"1","author":"MK Gupta","year":"2010","unstructured":"Gupta, M. K., Pollack, S. & Hutchings, J. J. Mesalamine induced symptom exacerbation of ulcerative colitis: Case report and brief discussion. World J. Gastrointest. Pharmacol. Ther. 1, 132\u2013134 (2010).","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"79207_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2147\/CEG.S86528","volume":"8","author":"S Matsumoto","year":"2015","unstructured":"Matsumoto, S. & Yoshida, Y. Efficacy of a pH-dependent controlled-release mesalazine based on clinical and endoscopic assessment for ulcerative colitis: A retrospective cohort study. Clin. Exp. Gastroenterol. 8, 225\u2013230 (2015).","journal-title":"Clin. Exp. Gastroenterol."},{"key":"79207_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.anai.2010.08.002","volume":"105","author":"Joint Task Force on Practice Parameters","year":"2010","unstructured":"Joint Task Force on Practice Parameters. Drug allergy: An updated practice parameter. Ann. Allergy Asthma Immunol. 105, 259\u2013273 (2010).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"79207_CR5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/apt.14430","volume":"47","author":"H Yu","year":"2018","unstructured":"Yu, H. et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Aliment Pharmacol. Ther. 47, 364\u2013370 (2018).","journal-title":"Aliment Pharmacol. Ther."},{"key":"79207_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/2050640619889763","volume":"8","author":"A Wisniewski","year":"2020","unstructured":"Wisniewski, A. et al. Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines. United Eur. Gastroenterol. J. 8, 303\u2013313 (2020).","journal-title":"United Eur. Gastroenterol. J."},{"key":"79207_CR7","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.2174\/1389450115666140821113330","volume":"15","author":"L Beaugeriie","year":"2014","unstructured":"Beaugeriie, L. Management of inflammatory bowel disease patients with a cancer history. Curr. Drug Targets. 15, 1042\u20131048 (2014).","journal-title":"Curr. Drug Targets."},{"key":"79207_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1590-8658(01)80108-0","volume":"33","author":"MC Di Paolo","year":"2001","unstructured":"Di Paolo, M. C. et al. Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: Report on tolerance and side-effects. Dig. Liver Dis. 33, 563\u2013569 (2001).","journal-title":"Dig. Liver Dis."},{"key":"79207_CR9","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1136\/gut.51.4.536","volume":"51","author":"RA Ransford","year":"2002","unstructured":"Ransford, R. A. & Langman, M. J. Sulphasalazine and mesalazine: Serious adverse reactions reevaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 51, 536\u2013539 (2002).","journal-title":"Gut"},{"key":"79207_CR10","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/ped.13235","volume":"59","author":"H Shimizu","year":"2017","unstructured":"Shimizu, H., Arai, K., Tang, J., Hosoi, K. & Funayama, R. 5-Aminosalicylate intolerance causing exacerbation in pediatric ulcerative colitis. Pediatr. Int. 59, 583\u2013587 (2017).","journal-title":"Pediatr. Int."},{"key":"79207_CR11","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.1002\/ibd.21323","volume":"17","author":"P Oustamanolakis","year":"2011","unstructured":"Oustamanolakis, P. & Koutroubakis, I. E. New desensitization regimen with mesalamine granules in a patient with ulcerative colitis and mesalamine intolerance. Inflamm. Bowel Dis. 17, E8-9 (2011).","journal-title":"Inflamm. Bowel Dis."},{"key":"79207_CR12","first-page":"127","volume":"4","author":"S Motoya","year":"2010","unstructured":"Motoya, S. et al. Mesalamine tolerance of ulcerative colitis. IBD Res. 4, 127\u2013131 (2010) (in Japanese).","journal-title":"IBD Res."},{"key":"79207_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.5217\/ir.2018.16.2.273","volume":"16","author":"D Saito","year":"2018","unstructured":"Saito, D. et al. Evaluation of the drug-induced lymphocyte stimulation test for diagnosing mesalazine allergy. Intest. Res. 16, 273\u2013281 (2018).","journal-title":"Intest. Res."},{"key":"79207_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5217\/ir.2019.00084","volume":"18","author":"S Mizuno","year":"2020","unstructured":"Mizuno, S. et al. 5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis. Intest. Res. 18, 69\u201378 (2020).","journal-title":"Intest. Res."},{"key":"79207_CR15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000453265","volume":"171","author":"WJ Pichler","year":"2016","unstructured":"Pichler, W. J. & Hausmann, O. Classification of drug hypersensitivity into allergic, p-i, and pseudo-allergic forms. Int. Arch. Allergy Immunol. 171, 166\u2013179 (2016).","journal-title":"Int. Arch. Allergy Immunol."},{"key":"79207_CR16","first-page":"243","volume":"53","author":"H Takikawa","year":"2010","unstructured":"Takikawa, H. Recent status of drug-induced liver injury and its problems in Japan. JMAJ. 53, 243\u2013247 (2010).","journal-title":"JMAJ."},{"key":"79207_CR17","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/j.1398-9995.2004.00547.x","volume":"59","author":"WJ Pichler","year":"2004","unstructured":"Pichler, W. J. & Tilch, J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 59, 809\u2013820 (2004).","journal-title":"Allergy"},{"key":"79207_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3109\/1547691X.2015.1008656","volume":"13","author":"A Popple","year":"2016","unstructured":"Popple, A. et al. The lymphocyte transformation test in allergic contact dermatitis: New opportunities. J. Immunotoxicol. 13, 84\u201391 (2016).","journal-title":"J. Immunotoxicol."},{"key":"79207_CR19","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1016\/0016-5085(95)90154-X","volume":"108","author":"JB Sturgeon","year":"1995","unstructured":"Sturgeon, J. B. et al. Exacerbation of chronic ulcerative colitis with mesalamine. Gastroenterology 108, 1889\u20131893 (1995).","journal-title":"Gastroenterology"},{"key":"79207_CR20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2169\/internalmedicine.1607-18","volume":"58","author":"R Tsuboi","year":"2019","unstructured":"Tsuboi, R. et al. A case of Crohn\u2019s disease with mesalazine allergy that was difficult to differentiate from comorbid ulcerative colitis. Intern. Med. 58, 649\u2013654 (2019).","journal-title":"Intern. Med."},{"key":"79207_CR21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1136\/bmj.282.6258.110","volume":"282","author":"CD Holdsworth","year":"1981","unstructured":"Holdsworth, C. D. Sulphasalazine desensitization. Br. Med. J. 282, 110 (1981).","journal-title":"Br. Med. J."},{"key":"79207_CR22","doi-asserted-by":"publisher","first-page":"512","DOI":"10.7326\/0003-4819-100-4-512","volume":"100","author":"BH Purdy","year":"1984","unstructured":"Purdy, B. H., Phillips, D. M. & Summers, R. W. Desensitization for sulfasalazine skin rash. Ann. Intern. Med. 100, 512\u2013514 (1984).","journal-title":"Ann. Intern. Med."},{"key":"79207_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00004836-198404000-00005","volume":"6","author":"BI Korelitz","year":"1984","unstructured":"Korelitz, B. I. et al. Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease. J. Clin. Gastroenterol. 6, 27\u201331 (1984).","journal-title":"J. Clin. Gastroenterol."},{"key":"79207_CR24","first-page":"1029","volume":"87","author":"V Tolia","year":"1992","unstructured":"Tolia, V. Sulfasalazine desensitization in children and adolescents with chronic inflammatory bowel disease. Am. J. Gastroenterol. 87, 1029\u20131032 (1992).","journal-title":"Am. J. Gastroenterol."},{"key":"79207_CR25","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.anai.2017.01.026","volume":"118","author":"JL Heath","year":"2017","unstructured":"Heath, J. L. et al. Mesalamine desensitization in a patient with treatment refractory ulcerative colitis and aspirin and nonsteroidal anti-inflammatory drug hypersensitivity. Ann. Allergy Asthma Immunol. 118, 518\u2013520 (2017).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"79207_CR26","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.jaip.2017.08.036","volume":"6","author":"CM Panganiban","year":"2018","unstructured":"Panganiban, C. M., Pourang, D. & Samant, S. A. A novel 2-day desensitization protocol to oral mesalamine. J. Allergy Clin. Immunol. Pract. 6, 695\u2013696 (2018).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"79207_CR27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3109\/00365521.2014.962608","volume":"50","author":"DJ Buurman","year":"2015","unstructured":"Buurman, D. J. et al. Ulcerative colitis patients with an inflammatory response upon mesalazine cannot be desensitized: A randomized study. Scand. J. Gastroenterol. 50, 399\u2013405 (2015).","journal-title":"Scand. J. Gastroenterol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79207-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79207-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79207-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:56:34Z","timestamp":1670374594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79207-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,17]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["79207"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-79207-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,17]]},"assertion":[{"value":"2 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22176"}}